James Arthur Bristol is Director at Deciphera Pharmaceuticals, Inc. (DCPH). They have made 15 open-market trades across 2 companies since 2019, most recently 2022-12-21.
CIK 0001715153
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $83K since 2022, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ERAS | BUY | 2022-12-21 | 2022-12-22 | $4.14 | $83K | -5.3% | -10.4% | -32.9% |
| DCPH | SELL | 2021-04-19 | 2021-04-21 | $46.19 | $383K | -0.0% | -27.9% | -26.2% |
| DCPH | SELL | 2021-04-12 | 2021-04-14 | $43.84 | $1.3M | +4.4% | -24.7% | -23.8% |
| DCPH | SELL | 2021-01-15 | 2021-01-20 | $50.29 | $352K | -9.0% | -11.8% | -8.9% |
| DCPH | SELL | 2020-10-09 | 2020-10-13 | $53.56 | $2.5M | +10.7% | +12.7% | -7.3% |
| DCPH | SELL | 2020-07-09 | 2020-07-13 | $54.98 | $2.6M | -6.7% | -10.5% | +6.7% |
| DCPH | SELL | 2020-04-09 | 2020-04-13 | $43.81 | $2.0M | -0.9% | +5.6% | +13.8% |
| DCPH | SELL | 2020-01-02 | 2020-01-06 | $57.65 | $2.6M | +17.6% | +17.6% | -26.1% |
| DCPH | SELL | 2019-11-01 | 2019-11-05 | $45.07 | $1.1M | +6.1% | +11.5% | +41.7% |
| DCPH | SELL | 2019-08-13 | 2019-08-13 | $39.97 | $2.0M | -0.7% | +0.4% | +33.7% |
| DCPH | SELL | 2019-08-13 | 2019-08-13 | $39.90 | $966K | -0.7% | +0.4% | +33.7% |
| DCPH | SELL | 2019-02-15 | 2019-02-19 | $28.04 | $499K | -2.2% | -16.4% | -22.3% |
| DCPH | SELL | 2019-02-14 | 2019-02-19 | $28.04 | $1.1M | -2.2% | -16.4% | -22.3% |
| DCPH | SELL | 2019-02-12 | 2019-02-14 | $28.01 | $180K | +5.3% | -9.3% | -16.4% |
| DCPH | SELL | 2019-02-05 | 2019-02-07 | $28.02 | $145K | +5.5% | -0.8% | -11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.